Pfizer Inc $ 38.35 -0.13 (-0.34%)
PFE News and Headlines - Pfizer Inc
GuruFocus Articles
Total 707
- 1
- 2
- 3
- 4
- 5
- 6
- 36
- 1
- 2
- 3
- 4
- 5
- 6
- 36
The last time I looked at AbbVie Inc. (ABBV) was following my early February purchase of the stock. At that time, I felt that shares had at least 30% upside. AbbVie recently reported earnings results, and nothing in the report has changed my thesis on the stock. I still believe that shares can offer at least a 30% increase in share price.
Quarterly highlights
AbbVie reported second-quarter earnings results on July 31. The company’s revenue increased 26.3% to $10.4 billion, beating Wall Street analysts’ estimates by almost $290 million. Adjusted earnings per share improved 8 cents, or 3.5%, to
According to the GuruFocus All-in-One Screener as of July 31, the following guru-held companies have high dividend yields and are trading with low price-earnings ratios.
Pfizer
Pfizer Inc.'s (PFE) dividend yield is 3.76% and the payout ratio is 0.52. Over the past 52 weeks, the stock has declined 1.71%. Shares are trading with a price-book ratio of 3.34 and a price-earnings ratio of 15.58. The company’s average yield was 3.55% over the past 10 years.
The pharmaceutical company has a market cap of $218.08 billion. The return on equity of 22.73% and return on assets of 8.68% are outperforming
Should the Covid-19 vaccine being developed by Pfizer Inc. (PFE) prove successful, it could give the company a $15 billion shot in the arm.
That’s the potential sales estimated by Bloomberg Intelligence analyst Sam Fazeli for a one-dose regimen of the vaccine, according to a FiercePharma article. Of course, that’s contingent on Pfizer being able to deliver 100 million doses of an effective inoculation.
Pfizer's deal also includes an option for another 500 million doses, RBC Capital Markets analyst Randall Stanicky pointed out, so "investors are increasingly seeing real opportunity here."
Meanwhile, Johnson & Johnson (JNJ), a late entrant to
It appears drug companies and their investors have little to fear from President Trump’s latest salvo aimed at holding down prescription drug prices.
Last week Trump signed a series of four executive orders he claimed will control pharmaceutical costs. But the action was quickly dismissed by many as being heavy on style and weak on substance. Some of the executive orders are unlikely to ever be implemented. Moreover, the orders require new regulations that ordinarily take months to finalize.
The proposals would help only a small group of people, according to comments by Peter Maybarduk, director of Public Citizen’s Access
The Dow Jones Industrial Average closed at 27,005.84 on Wednesday with a gain of 165.44 points or 0.62%. The S&P 500 closed at 3,276.02 for a gain of 18.72 points or 0.57%. The Nasdaq Composite closed at 10,706.13 for a gain of 25.76 points or 0.24%. The VIX Volatility Index was lower at 24.41 for a loss of 0.43 points or -1.73%.
Wednesday’s Market Movers
Pfizer and BioNTech received a $1.95 billion order from the U.S. government for the partnership’s Covid-19 vaccine. Pfizer led gains for the day, up nearly 5% and contributing to the Dow’s return for the day.
One strategy to come across value opportunities is to screen for stocks with an enticing forward price-earnings ratio.
The following three stocks have a forward price-earnings ratio that stands below the S&P 500 index's historical average of 15. Estimates of future earnings are based on data from Morningstar analysts.
Pfizer Inc
The first company that meets the criteria is Pfizer Inc (PFE), the New York-based drug giant.
Pfizer Inc has a forward price-earnings ratio of 12.8 (versus the industry median of 19.42), which results from Friday’s share price of $36.25 and analyst expectations for earnings per share (EPS)
Previously, I listed the 15 members of Big Pharma that are expected to record the highest sales in 2026, as reported by EvaluatePharma. Now we’ll look at the products and strategies that will propel the top five companies’ revenue.
Roche Holding AG (RHHBY)
- Estimated 2026 sales: $61.9 billion
- 2019 sales: $48.2 billion
- 2019 to 2026 CAGR: 3.62%
Although the Swiss company is expected to suffer a $10 billion shortfall when three of its top-selling cancer drugs lose exclusivity, replacements are expected to step into the breach. That was the case in the first quarter, when two
Thanks to the introduction of drugs in three major disease areas, Roche (RHHBY) is expected to retain its position as the number one member of Big Pharma in terms of sales, according to a report from Evaluate Pharma.
The Swiss company’s revenues are forecast to reach $62 billion in 2026, growing at a compound rate of more than 3.6% from 2019. Pfizer Inc. (PFE) is expected to capture the number two spot with sales of just over $56 billion. Others reaching the $50 billion plus level are Johnson & Johnson (JNJ), Novartis (NVS), AbbVie Inc.(ABBV) and Merck & Co. Inc.
Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc. (BMRN) has the most to gain. If the company’s Roctavian gets greenlighted by the Food and Drug Administration, it will become the first gene therapy for one of the world’s highest-profile inherited diseases, hemophilia A.
Hemophilia is a rare hereditary bleeding disorder that occurs in a relatively small number of patients around the world. Its cause is a missing or deficient protein needed for blood clotting. Hemophilia A occurs in one in 5,000 live male births. It is about four times as common
As the world awaits a potential solution to counter the Covid-19 pandemic, a number of pharma and biotech companies have their candidates going through different stages of trials.
The total number of confirmed Covid-19 cases across the globe is nearing the 12 million mark, with over 3 million in the U.S. alone. Governments have thus been putting increasing pressure on scientists and pharmaceutical companies to come up with a drug or a vaccine to handle the situation. The process has been slow, which was expected as a successful treatment has never before been developed for any other type of coronavirus,
Immunomedics (IMMU) has been in the news for a recent change of CEO. The company’s President and CEO Harout Semerjian stepped down and was replaced by Dr. Behzad Aghazadeh.
The company has also been making some fantastic progress on antibody-drug conjugates (ADCs), particularly Trodelvy, which was used to treat its first commerical in the past few weeks. The drug is expected to drive revenues for Immunomedics in 2020.
The company has some promising collaborations with giants such as AstraZeneca (AZN) and Roche (OTCQX:RHHBY). It has also raised funds recently to fund its research for the coming quarters.
In my
Meet a drug company with an extraordinary return on equity: GlaxoSmithKline PLC (GSK).
Its return on equity is extremely volatile, ranging from 25.14% for 2016 to 313.03% for 2017. That makes 2019’s return on equity of 61.7% appear almost normal. But, of course, we know few companies have such a high return on investors’ money.
Does that make it an immediate buy stock, especially since its dividend falls into the category of high-yield? More than a dozen gurus apparently think so, and it does have a place on the
The Dow Jones Industrial Average closed at 25,827.36 on Thursday with a gain of 92.39 points or 0.36%. The S&P 500 closed at 3,130.01 for a gain of 14.15 points or 0.45%. The Nasdaq Composite closed at 10,207.63 for a gain of 53.00 points or 0.52%. The VIX Volatility Index was lower at 27.77 for a loss of 0.85 points or -2.97%.
For the week, the Nasdaq gained 4.6%, the S&P 500 gained 4.0% and the Dow Jones gained 3.3%. For the year, the Nasdaq has a gain of 13.76%, the S&P 500 is down 3.12% and the Dow Jones
Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades. The +20% rebound in the 2nd quarter S&P 500 index was the best result achieved since 1998. Moreover, the Dow Jones Industrial Average saw its largest quarterly gain (+18%) since 1987, and the technology-heavy NASDAQ index (+31%) saw the most appreciation since 2001. While a snap-back after a shockingly dismal 1st quarter should come as no surprise to many investors, the pace of this rebound is unlikely to be sustainable at this trajectory, given the challenging economic
As the world continues to fight the Covid-19 pandemic, one highly promising sector that has been put on the backburner by the investor community is the green energy space. It only appears to be a matter of time before this comes back to focus, which is when companies like FuelCell Energy Inc. (FCEL) will be back in the limelight.
FuelCell Energy is one of the oldest clean energy companies, and it managed to deliver an excellent quarterly result even in the lockdown situation. As it readies itself to issue an additional $75 million worth of stock, the price is falling
On the heels of research deals with two small biotechs, shares of Sarepta Therapeutics Inc. (SRPT) hit their all-time high of more than $172 on June 23.
The share price of the Cambridge, Massachusetts-based biopharmaceutical company has doubled since mid-March. It has a market cap of more than $13 billion.
Sarepta has made a host of deals in the past several years that have made gene therapy a key part of its business, which had been dominated by drugs for muscular dystrophy. One of those pacts, with Roche (RHHBY), could be worth more than $3 billion.
Sarepta currently has a
Pfizer Inc (PFE) has joined the list of High-Yield Dividend Screener & High-Dividend Yield Stocks in Guru's Portfolios.
Based on the share price on Monday, June 22, it offers a dividend yield of 4.43%, more than double the average of the S&P 500, while its share price has been going down—and began going down before Covid-19 was a factor :
Specifically, the price took a dive in the first couple of weeks of July 2019, just before patent protection on the fibromyalgia drug Lyrica expired on July 19th and a generic
If it’s true that “you have to spend money to make money” and “you get what you pay for,” then investors should pile into the stocks of the pharmaceutical companies plowing the most into research and development.
At the top of that list are Roche (RHHBY), Johnson & Johnson (JNJ), Merck & Co. Inc. (MRK) and Novartis (NVS). Last year, these four--along with six other members of Big Pharma-- spent a collective $82 billion in their quest for new drugs, diagnostics and vaccines, around $4 billion more than the previous year, according to FierceBiotech.
But a word of caution here:
Among the most highly-paid pharmaceutical CEOs in 2019, Vertex Pharmaceuticals Inc.’s (VRTX) Jeffrey Leiden has given shareholders the biggest bang for the buck. Although he was the only the 9th highest paid (out of 15 ranked), under Leiden’s stewardship the company’s share price rose 53% in the past year.
On the other end of the spectrum was Albert Bourla of Pfizer Inc. (PFE), who raked in a paltry $18 million for shareholders. The company’s share price has plummeted more than 15% during the past 12 months.
The list of the 15 highest-paid CEOs in pharma was
Due to the timing of contributions to our IRAs, my wife and I were able to make three new stock purchases over the last two weeks. We invest nearly all of our retirement capital in dividend growth stocks, as we plan to live off dividend income when we are able to retire in 20 years or so.
When selecting investments, we look at dividend growth stocks stocks trading below the 10-year average valuation, which gives a margin of safety. Here are the purchases we made and our reasons for doing so.
Pfizer
We purchased shares of Pfizer Inc. (PFE) on
Headlines
Total 521
- 1
- 2
- 3
- 4
- 5
- 6
- 1
- 2
- 3
- 4
- 5
- 6
- 1
- 2
- 3
- 4
- 5
- 6